. Author manuscript; available in PMC: 2010 Jul 9.

Published in final edited form as: J Urol. 2009 Mar 14;181(5):1998–2008. doi: 10.1016/j.juro.2009.01.047

Table 3.

Post hoc analyses of completed randomized controlled trials

Study	Population	Groups Compared	No. CV Deaths	CV Mortality	Comments/Conclusions
Pooled data⁵¹	Combination of trials for men treated for intermediate or high risk prostate Ca	6 Mos adjuvant ADT vs no ADT	34	18 CV deaths with ADT, 16 without ADT	Statistical analysis confined only to men older than 65 yrs event rate was equivalent but CV deaths sooner with ADT
RTOG 85-31⁴⁶	Unfavorable prognosis prostate Ca (T3 tumor or nodal involvement)	RT + indefinite ADT vs RT alone	117	8.4% With ADT, 11.4% without ADT	No significant difference between treatment groups (p = 0.17)
RTOG 86-10⁴⁷	Locally advanced prostate Ca	RT + 4 mos combined ADT vs RT alone	57	14% With ADT, 11% without ADT	No significant difference between treatment groups (p = 0.32)
RTOG 92-02⁴⁸	Locally advanced prostate Ca	RT + ADT (28 mos) vs RT + ADT (4 mos)	185	5-Yr CV mortality, 5.9% with 28 mos ADT, 4.8% with 4 mos ADT	No significant difference between treatment groups (p = 0.58)
EORTC 30891⁴⁹	Prostate Ca not suitable for local treatment	Immediate ADT vs ADT deferred until symptomatic	185	17.9% With immediate ADT, 19.7% with deferred ADT	No significant difference between treatment groups